

Investigational Products Currently in (or Planned for) Clinical Trials



1. Chen P, et al. N Engl J Med. 2020. doi:10.1056/NEJMoa2029849; 2. Gottlieb RL et al. JAMA 2021; doi:10.1001/jama.2021.0202 3. Kalil AC et al. NEJM 2020; doi: 10.1056NEJMoa2031994

BLAZE-1 Ambulatory Setting; Study Design



Company Confidential © 2020 Eli Lilly and Company

BLAZE-1 Phase 2; Bamlanivimab Monotherapy

Covid-19 Related Hospitalization or ER Visit Within 28 Days After Treatment

ALL SUBJECTS

	N	Events	Rate
Placebo	156	9	5.8%
Bamlanivimab 700 mg	101	1	1.0%
Bamlanivimab 2800 mg	107	2	1.9%
Bamlanivimab 7000 mg	101	2	2.0%
All Bamlanivimab Doses	309	5	1.6%

~72% reduction vs. placebo

AGE ≥ 65 OR BMI ≥ 35

	N	Events	Rate
Placebo	69	7	10.1%
Bamlanivimab 700 mg	46	1	2.2%
Bamlanivimab 2800 mg	46	1	2.2%
Bamlanivimab 7000 mg	1,1,	2	4.5%
All Bamlanivimab Doses	136	4	2.9%

-71% reduction vs. placebo

Adapted from: SARS-CoV-2 Neutralizing Antibody Program Update Presentation; January 26, 2021; https://investor.lilly.com/static-files/081a5ef7-f5d6-4acc-b0d2-7ae4daf9e953

Company Confidential © 2020 Eli Lilly and Company

BLAZE-1 Phase 3; Primary Endpoint

COVID-19 RELATED HOSPITALIZATION OR DEATH BY ANY CAUSE BY DAY 29

DEATH BY ANY CAUSE BY DAY 29

	N	Events	Rate	p
Placebo	517	36	7.0%	-
Bamlanivimab 2800 mg + Etesevimab 2800 mg	518	11	2.1%	0.0004

70% reduction vs. placebo

	N	Events	Rate
Placebo	517	10 ⁺	1.9%
Bamlanivimab 2800 mg + Etesevimab 2800 mg	518	0	0%

No deaths of any cause with antibody therapy

*8 of 10 deaths were deemed COVID-19 related

Adapted from: SARS-CoV-2 Neutralizing Antibody Program Update Presentation; January 26, 2021; https://investor.lilly.com/static-files/081a5ef7-f5d6-4acc-b0d2-7ae4daf9e953

Company Confidential © 2020 Eli Lilly and Company

Bamlanivimab Emergency Use Authorization and Administration Guidance

BAMLANIVIMAB MUST BE ADMINISTERED BY INTRAVENOUS (IV) INFUSION

Health care providers must submit a report on all medication errors and **ALL SERIOUS ADVERSE EVENTS** related to bamlanivimab.

Bamlanivimab may be used for the **treatment of mild-to-moderate COVID-19 in adults and pediatric patients** with positive results of direct SARS-CoV-2 viral testing who are ≥ 12 years of age weighing at least 40 kg, and **who are at high-risk** for progressing to severe COVID-19 and/or hospitalization.

Bamlanivimab <u>should not be</u> used in patients hospitalized or who require oxygen due to COVID-19 respiratory disease.

www.bamlanivimabhcpinfo.com

High risk is defined as patients who meet at least one of the following criteria:

- Have a body mass index (BMI) ≥ 35
- Have chronic kidney disease
- Have diabetes
- · Have immunosuppressive disease
- · Are currently receiving immunosuppressive treatment
- Are ≥ 65 years of age
- Are ≥ 55 years of age AND have
 - CVD OR hypertension OR COPD/other chronic respiratory disease
- Are 12-17 years of age AND have
 - BMI ≥85th percentile for their age and gender OR sickle cell disease OR congenital/acquired heart disease OR neurodevelopmental disorders OR medical-related technological dependence OR asthma/reactive airway/chronic respiratory disease that requires daily medication control

company confidential © 2020 Eli Elity and company